Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
Did you mean: (nivolumab)?
328 results
  • Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications. [Review]
    Semin Immunol 2019; 42:101295Krueger J, Rudd CE, Taylor A
  • The past few years have witnessed exciting progress in the application of immune check-point blockade (ICB) for the treatment of various human cancers. ICB was first used against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to demonstrate durable anti-tumor responses followed by ICB against programmed cell death-1 (PD-1) or its ligand, PD-L1. Present approaches involve the use of combinat…
  • Immune checkpoint inhibition for the treatment of renal cell carcinoma. [Journal Article]
    Expert Opin Biol Ther 2019; :1-12Stühler V, Maas JM, … Bedke J
  • Introduction: The systemic therapy in metastatic renal cell carcinoma (mRCC) is moving from tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors to immune checkpoint inhibitors and its combination with TKIs. Areas covered: This review provides a general overview using immune checkpoint inhibition for the treatment of RCC. Clinical results from conducted and ongoin…
  • Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors. [Review]
    Int J Mol Sci 2019; 20(19)Grywalska E, Sobstyl M, … Roliński J
  • Despite the ongoing progress in cancer research, the global cancer burden has increased to 18.1 million new cases and 9.6 million deaths in 2018. Gynecological cancers, such as ovarian, endometrial, and cervical cancers, considerably contribute to global cancer burden, leading to $5,862.6, $2,945.7, and $1,543.9 million of annual costs of cancer care, respectively. Thus, the development of effect…
  • Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma. [Case Reports]
    Case Rep Oncol 2019 May-Aug; 12(2):639-643Tun Min S, Nordman IIC, Tran HA
  • Merkel cell carcinoma is a rare but aggressive skin cancer. Response to chemotherapy is not durable but avelumab, an anti-PD-L1 inhibitor, showed promising ongoing response in a phase II trial. Checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (irAE). We describe the first reported case of hypercalcaemia secon…
New Search Next